1. Scrip
  2. >>Archive

Bitterman and Brownlie join board at RXi

 
• By Gemma Sharman

RNAi therapeutics company RXi Pharmaceuticals has appointed Robert Bitterman and Keith Brownlie to its board of directors. Mr Bitterman currently serves as president and CEO of Cutanea Life Sciences, a wholly owned subsidiary of Maruho Company. Mr Brownlie joins RXi following a 36-year career at Ernst & Young. For the last 20 years before his retirement in 2010, he was Metro New York Area Life Sciences Industry Leader at the company. Mr Brownlie also serves on the boards of Epicept and Soligenix.

RNAi therapeutics company RXi Pharmaceuticals has appointed Robert Bitterman and Keith Brownlie to its board of directors. Mr Bitterman currently serves as president and CEO of Cutanea Life Sciences, a wholly owned subsidiary of Maruho Company. Mr Brownlie joins RXi following a 36-year career at Ernst & Young. For the last 20 years before his retirement in 2010, he was Metro New York Area Life Sciences Industry Leader at the company. Mr Brownlie also serves on the boards of Epicept and Soligenix.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By Joseph Haas

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

NewAmsterdam’s CETP Inhibitor Improves Alzheimer’s Biomarkers

 
• By Mandy Jackson

Data from the BROADWAY trial testing LDL-C reduction in adults with ASCVD showed that obicetrapib improved Alzheimer’s disease biomarkers, including tau and amyloid. Analysts think the data could differentiate obicetrapib against competitors in the cholesterol market.

With ACIP Upheaval, Merck & Co. Among Those Left In A Lurch

 
• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.